Expertise in
5
conditions

Dr. Joseph Baar

Hematology | Oncology
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 

Overview

Joseph Baar is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Baar is highly rated in 5 conditions, according to our data. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

University Hospitals
11100 Euclid Ave, Cleveland, OH 44106
Other Locations
Office
24701 Euclid Ave Fl 3, Euclid, OH 44117

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Drug
Study Drug: Carvedilol
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 20, 2019
Intervention Type: Drug, Other
Study Phase: Phase 2
View 6 Less Clinical Trials

4 Total Publications

Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.
Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 05, 2023
Similar Doctors
Jason Valent
Expertise in
25
conditions
Dr. Jason Valent
Hematology | Oncology
Expertise in
25
conditions
Dr. Jason Valent
Hematology | Oncology

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (0.8 miles away)
216-444-6833
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jason Valent is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Valent is highly rated in 25 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration.

Expertise in
24
conditions
Dr. Brad Pohlman
Hematology | Oncology
Expertise in
24
conditions
Dr. Brad Pohlman
Hematology | Oncology

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (0.8 miles away)
216-445-6070
Languages Spoken:
English
See accepted insurances

Brad Pohlman is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Pohlman is highly rated in 24 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
33
conditions
Dr. Robert Dean
Hematology | Oncology
Expertise in
33
conditions
Dr. Robert Dean
Hematology | Oncology

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (0.8 miles away)
216-444-6833
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Dean is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Dean is highly rated in 33 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Joseph Baar

How do I make an appointment with Dr. Joseph Baar?

You can book an appointment with Dr. Joseph Baar by calling their office at 216-844-8500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joseph Baar a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joseph Baar is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joseph Baar specialize in?

While Dr. Joseph Baar is a Hematology, they have specific expertise in Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Joseph Baar participate in research or clinical trials?

Yes. Dr. Joseph Baar has published 4 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Joseph Baar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joseph Baar accept my insurance?

Dr. Joseph Baar accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 216-844-8500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baar's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile